Compare PLG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | SLN |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | Canada | United Kingdom |
| Employees | N/A | 116 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.4M | 236.2M |
| IPO Year | 2002 | N/A |
| Metric | PLG | SLN |
|---|---|---|
| Price | $1.58 | $6.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | ★ 2.2M | 255.6K |
| Earning Date | 04-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.97 |
| 52 Week High | $4.04 | $7.91 |
| Indicator | PLG | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 26.27 | 52.83 |
| Support Level | $1.39 | $5.79 |
| Resistance Level | $1.69 | $7.40 |
| Average True Range (ATR) | 0.15 | 0.69 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 3.16 | 42.71 |
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.